Depicting the landscape of gut microbial-metabolic interaction and microbial-host immune heterogeneity in deficient and proficient DNA mismatch repair colorectal cancers

Background Accumulating evidence has indicated the role of gut microbiota in remodeling host immune signatures, but various interplays underlying colorectal cancers (CRC) with deficient DNA mismatch repair (dMMR) and proficient DNA mismatch repair (pMMR) remain poorly understood. This study aims to decipher the gut microbiome-host immune interactions between dMMR and pMMR CRC. Method We performed metagenomic sequencing and metabolomic analysis of fecal samples from a cohort encompassing 455 participants, including 21 dMMR CRC, 207 pMMR CRC, and 227 healthy controls. Among them, 50 tumor samples collected from 5 dMMR CRC and 45 pMMR CRC were conducted bulk RNA sequencing. Results Pronounced microbiota and metabolic heterogeneity were identified with 211 dMMR-enriched species, such as Fusobacterium nucleatum and Akkermansia muciniphila, 2 dMMR-depleted species, such as Flavonifractor plautii, 13 dMMR-enriched metabolites, such as retinoic acid, and 77 dMMR-depleted metabolites, such as lactic acid, succinic acid, and 2,3-dihydroxyvaleric acid. F. plautii was enriched in pMMR CRC and it was positively associated with fatty acid degradation, which might account for the accumulation of dMMR-depleted metabolites classified as short chain organic acid (lactic acid, succinic acid, and 2,3-dihydroxyvaleric acid) in pMMR CRC. The microbial-metabolic association analysis revealed the characterization of pMMR CRC as the accumulation of lactate induced by the depletion of specific gut microbiota which was negatively associated with antitumor immune, whereas the nucleotide metabolism and peptide degradation mediated by dMMR-enriched species characterized dMMR CRC. MMR-specific metabolic landscapes were related to distinctive immune features, such as CD8+ T cells, dendritic cells and M2-like macrophages. Conclusions Our mutiomics results delineate a heterogeneous landscape of microbiome-host immune interactions within dMMR and pMMR CRC from aspects of bacterial communities, metabolic features, and correlation with immunocyte compartment, which infers the underlying mechanism of heterogeneous immune responses.

[1]  S. Bullman,et al.  Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer , 2022, Nature.

[2]  M. Blaser,et al.  Tumor microbiome links cellular programs and immunity in pancreatic cancer. , 2022, Cancer cell.

[3]  Xinxiang Li,et al.  Integrated metagenomic and metabolomic analysis reveals distinct gut-microbiome-derived phenotypes in early-onset colorectal cancer , 2022, Gut.

[4]  H. Vlamakis,et al.  Akkermansia muciniphila phospholipid induces homeostatic immune responses , 2022, Nature.

[5]  Liang Zhou,et al.  Fusobacterium nucleatum impairs DNA mismatch repair and stability in patients with squamous cell carcinoma of the head and neck , 2022, Cancer.

[6]  M. Gonen,et al.  PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. , 2022, The New England journal of medicine.

[7]  F. Sinicrope,et al.  Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade. , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  W. D. de Vos,et al.  Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms , 2022, Nature Reviews Gastroenterology & Hepatology.

[9]  Hongzhong Li,et al.  Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies , 2022, Journal of Hematology & Oncology.

[10]  J. Badger,et al.  Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 , 2022, Nature Medicine.

[11]  T. Spector,et al.  Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma , 2022, Nature Medicine.

[12]  N. Segata,et al.  Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer , 2022, Nature Medicine.

[13]  D. Hanahan Hallmarks of Cancer: New Dimensions. , 2022, Cancer discovery.

[14]  M. Tsuboi,et al.  Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. , 2022, Cancer cell.

[15]  M. Kloor,et al.  The different immune profiles of normal colonic mucosa in cancer-free Lynch syndrome carriers and Lynch syndrome colorectal cancer patients. , 2021, Gastroenterology.

[16]  H. Qin,et al.  Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer , 2021, Signal Transduction and Targeted Therapy.

[17]  R. Rodrigues,et al.  Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment , 2021, Cell.

[18]  W. Yuan,et al.  Interaction between intestinal microbiota and tumour immunity in the tumour microenvironment , 2021, Immunology.

[19]  M. Sawyer,et al.  Nivolumab + low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  J. Badger,et al.  Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients , 2021, Science.

[21]  Yang Gu,et al.  Discovery of an ene-reductase for initiating flavone and flavonol catabolism in gut bacteria , 2021, Nature communications.

[22]  Timothy L. Tickle,et al.  Multivariable association discovery in population-scale meta-omics studies , 2021, bioRxiv.

[23]  Pengxian Tao,et al.  Effects of Antibiotic Use on Outcomes in Cancer Patients Treated Using Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. , 2020, Journal of immunotherapy.

[24]  M. Kloor,et al.  The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution , 2020, Nature Communications.

[25]  E. Allen-Vercoe,et al.  A Microbiota-Derived Metabolite Augments Cancer Immunotherapy Responses in Mice. , 2020, Cancer cell.

[26]  Ping-Chih Ho,et al.  Lactate modulation of immune responses in inflammatory versus tumour microenvironments , 2020, Nature Reviews Immunology.

[27]  Michelle L. Reyzer,et al.  Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells , 2020, The Journal of experimental medicine.

[28]  A. Broeks,et al.  Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers , 2020, Nature Medicine.

[29]  A. Jemal,et al.  Colorectal cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[30]  I. Asangani,et al.  Tumor-Derived Retinoic Acid Regulates Intratumoral Monocyte Differentiation to Promote Immune Suppression , 2020, Cell.

[31]  M. Scholz,et al.  Propionic Acid Shapes the Multiple Sclerosis Disease Course by an Immunomodulatory Mechanism , 2020, Cell.

[32]  Rob Knight,et al.  Microbiome analyses of blood and tissues suggest cancer diagnostic approach , 2020, Nature.

[33]  L. Ivashkiv The hypoxia–lactate axis tempers inflammation , 2019, Nature Reviews Immunology.

[34]  K. Kogure,et al.  Biological Functions of α-Tocopheryl Succinate. , 2019, Journal of nutritional science and vitaminology.

[35]  L. Zitvogel,et al.  The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor? , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  Steven L Salzberg,et al.  Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype , 2019, Nature Biotechnology.

[37]  Jun Yu,et al.  Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity , 2019, Nature Microbiology.

[38]  E. Giovannucci,et al.  Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies , 2019, Nature Reviews Gastroenterology & Hepatology.

[39]  D. Plichta,et al.  Akkermansia muciniphila induces intestinal adaptive immune responses during homeostasis , 2019, Science.

[40]  Ash A. Alizadeh,et al.  Determining cell-type abundance and expression from bulk tissues with digital cytometry , 2019, Nature Biotechnology.

[41]  A. Goel,et al.  DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers. , 2019, Gastroenterology.

[42]  Namrata Iyer,et al.  Commensals Suppress Intestinal Epithelial Cell Retinoic Acid Synthesis to Regulate Interleukin‐22 Activity and Prevent Microbial Dysbiosis , 2018, Immunity.

[43]  Casey M. Theriot,et al.  Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells , 2018, Science.

[44]  J. Slotta-Huspenina,et al.  Gut microbiota modulate T cell trafficking into human colorectal cancer , 2018, Gut.

[45]  M. Sawyer,et al.  Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Laurence Zitvogel,et al.  Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors , 2018, Science.

[47]  Riyue Bao,et al.  The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients , 2018, Science.

[48]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[49]  Fangfang Guo,et al.  Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy , 2017, Cell.

[50]  D. Wallace,et al.  Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments. , 2017, Cell metabolism.

[51]  A. Eggermont,et al.  Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  N. Bhattacharya,et al.  Normalizing Microbiota-Induced Retinoic Acid Deficiency Stimulates Protective CD8(+) T Cell-Mediated Immunity in Colorectal Cancer. , 2016, Immunity.

[53]  J. Rathmell,et al.  A guide to immunometabolism for immunologists , 2016, Nature Reviews Immunology.

[54]  F. Bäckhed,et al.  From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites , 2016, Cell.

[55]  M. Kloor,et al.  The Immune Biology of Microsatellite-Unstable Cancer. , 2016, Trends in cancer.

[56]  F. Ginhoux,et al.  Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota , 2015, Science.

[57]  Mingyang Song,et al.  Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis , 2015, Gut.

[58]  B. Vogelstein,et al.  PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  Christopher D. Heinen,et al.  Milestones of Lynch syndrome: 1895–2015 , 2015, Nature Reviews Cancer.

[60]  M. Meyerson,et al.  Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. , 2013, Cell host & microbe.

[61]  Wei Li,et al.  RSeQC: quality control of RNA-seq experiments , 2012, Bioinform..

[62]  D. Kominsky,et al.  Retinoic acid attenuates ileitis by restoring the balance between T-helper 17 and T regulatory cells. , 2011, Gastroenterology.

[63]  S. Gruber,et al.  Microsatellite instability in colorectal cancer—the stable evidence , 2010, Nature Reviews Clinical Oncology.

[64]  Davis J. McCarthy,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[65]  J. Jiricny The multifaceted mismatch-repair system , 2006, Nature Reviews Molecular Cell Biology.

[66]  K. Kinzler,et al.  The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints , 2015, Journal of Immunotherapy for Cancer.